Search Results - "López Pousa, A"

A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer by Hitt, R., Grau, J.J., López-Pousa, A., Berrocal, A., García-Girón, C., Irigoyen, A., Sastre, J., Martínez-Trufero, J., Brandariz Castelo, J.A., Verger, E., Cruz-Hernández, J.J., Almodóvar, C., Cortés-Funes, H., Escobar, Y., Fonseca-Sánchez, E., Galcerán, J.C., Guix, M., Isla-Casado, D., Jara-Sánchez, C., Leitão-Silva, M.R., Mel-Lorenzo, J.R., Pastor-Borgoñón, M., Pastor-Gaitán, P., Rodríguez-Jaráiz, A., Millán, J.M., Satrustegui-Galdona, J., Moreno, M., Estefanía, E., Santiago, E., García, J.J.

“…Concurrent chemoradiotherapy (CCRT) is the standard treatment for patients with unresectable, nonmetastatic locoregionally advanced squamous-cell carcinoma of…”
Get full text

Giant cell tumour of bone: new treatments in development by López-Pousa, A., Broto, J. Martín, Garrido, T., Vázquez, J.

“…Giant cell tumour of bone (GCTB) is a benign osteolytic tumour with three main cellular components: multinucleated osteoclast-like giant cells, mononuclear…”
Get full text

Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial by Hitt, R., Iglesias, L., López-Pousa, A., Berrocal-Jaime, A., Grau, J. J., García-Girón, C., Martínez-Trufero, J., Guix, M., Lambea-Sorrosal, J., del Barco-Morillo, E., León-Vintró, X., Cunquero-Tomas, A. J., Baste, N., Ocaña, A., Cruz-Hernández, J. J.

“…Background Our previous phase-3 study (TTCC 2503) failed to show overall survival advantage of 2 induction chemotherapy (IC) regimens followed by standard…”
Get full text

SEOM Clinical Guideline of management of soft-tissue sarcoma (2016) by López-Pousa, A., Martin Broto, J., Martinez Trufero, J., Sevilla, I., Valverde, C., Alvarez, R., Carrasco Alvarez, J. A., Cruz Jurado, J., Hindi, N., Garcia del Muro, X.

“…Soft-tissue sarcomas are uncommon and heterogeneous tumors of mesenchymal origin. A soft-tissue mass that is increasing in size, greater than 5 cm, or located…”
Get full text

Evidence mapping based on systematic reviews of therapeutic interventions for soft tissue sarcomas by Ballesteros, M., Montero, N., López-Pousa, A., Urrútia, G., Solà, I., Rada, G., Pardo-Hernandez, H., Bonfill, X.

“…Purpose Soft tissue sarcomas are a heterogeneous group of rare tumours of mesenchymal origin. Evidence mapping is one of the most didactic and friendly…”
Get full text

KRAS genetic variant as a prognostic factor for recurrence in resectable non-small cell lung cancer by Sullivan, I., Salazar, J., Arqueros, C., Andrés, M., Sebio, A., Majem, M., Szafranska, J., Martínez, E., Páez, D., López-Pousa, A., Baiget, M., Barnadas, A.

“…Purpose Several angiogenic prognostic markers are under investigation because of their potential clinical utility, aiming to improve patient outcomes. We…”
Get full text

Risk assessment model for first-cycle chemotherapy-induced neutropenia in patients with solid tumours by LÓPEZ-POUSA, A., RIFÀ, J., CASAS DE TEJERINA, A., GONZÁLEZ-LARRIBA, J.L., IGLESIAS, C., GASQUET, J.A., CARRATO, A.

“…LÓPEZ‐POUSA A., RIFÀ J., CASAS DE TEJERINA A., GONZÁLEZ‐LARRIBA J.L., IGLESIAS C., GASQUET J.A. & CARRATO A. (2010) European Journal of Cancer Care Risk…”
Get full text

Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study by Martín-Liberal, J., López-Pousa, A., Broto, J. Martín, Cubedo, R., Gallego, O., Brendel, E., Tirado, O. M., del Muro, X. García

“…Summary Background This phase I trial assessed safety, pharmacokinetics (PK), dose limiting toxicity (DLT), maximum tolerated dose and recommended dose (RD) of…”
Get full text

Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up by Strauss, S.J., Frezza, A.M., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Blay, J.Y., Bolle, S., Bonvalot, S., Boukovinas, I., Bovee, J.V.M.G., Boye, K., Brennan, B., Brodowicz, T., Buonadonna, A., de Álava, E., Dei Tos, A.P., Garcia del Muro, X., Dufresne, A., Eriksson, M., Fagioli, F., Fedenko, A., Ferraresi, V., Ferrari, A., Gaspar, N., Gasperoni, S., Gelderblom, H., Gouin, F., Grignani, G., Gronchi, A., Haas, R., Hassan, A.B., Hecker-Nolting, S., Hindi, N., Hohenberger, P., Joensuu, H., Jones, R.L., Jungels, C., Jutte, P., Kager, L., Kasper, B., Kawai, A., Kopeckova, K., Krákorová, D.A., Le Cesne, A., Le Grange, F., Legius, E., Leithner, A., López Pousa, A., Martin-Broto, J., Merimsky, O., Messiou, C., Miah, A.B., Mir, O., Montemurro, M., Morland, B., Morosi, C., Palmerini, E., Pantaleo, M.A., Piana, R., Piperno-Neumann, S., Reichardt, P., Rutkowski, P., Safwat, A.A., Sangalli, C., Sbaraglia, M., Scheipl, S., Schöffski, P., Sleijfer, S., Strauss, D., Sundby Hall, K., Trama, A., Unk, M., van de Sande, M.A.J., van der Graaf, W.T.A., van Houdt, W.J., Frebourg, T., Ladenstein, R., Casali, P.G., Stacchiotti, S.

“…•This Clinical Practice Guideline provides key recommendations on the management of bone sarcomas.•Recommendations have been agreed following a consensus…”
Get full text

Value of FDG-PET for monitoring treatment response in patients with advanced GIST refractory to high-dose imatinib. A multicenter GEIS study by Fuster, D, Ayuso, J R, Poveda, A, Cubedo, R, Casado, A, Martínez-Trufero, J, López-Pousa, A, Del Muro, X G, Lomeña, F, Maurel, J, Pons, F

“…The aim of this study was to evaluate the utility of positron emission tomography with 18F-fluorodeoxyglucose (FDG-PET) in monitoring response in refractory…”
Get full text

Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas by LOSA, R, FRA, J, ESCUDERO, P, ESTEBAN, E, BUESA, José M, LOPEZ-POUSA, A, SIERRA, M, GOITIA, A, UNA, E, NADAL, R, GARCIA DEL MURO, J, GION, M, MAUREL, J

“…Based on the promising results of a Phase I study with a combination of gemcitabine and DTIC performed in advanced soft tissue sarcoma (ASTS) patients, and due…”
Get full text

Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group by Gronchi, A., Stacchiotti, S., Verderio, P., Ferrari, S., Martin Broto, J., Lopez-Pousa, A., Llombart-Bosch, A., Dei Tos, A.P., Collini, P., Jurado, J.C.r.u.z., De Paoli, A., Donati, D.M., Poveda, A., Quagliuolo, V., Comandone, A., Grignani, G., Morosi, C., Messina, A., De Sanctis, R., Bottelli, S., Palassini, E., Casali, P.G., Picci, P.i.e.r.o.

“…The equivalence of a short full-dose regimen of neoadjuvant CT with anthracycline-ifosfamide compared with standard dosing in localized high-risk soft tissue…”
Get full text

Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS) by Martin-Broto, J., Redondo, A., Valverde, C., Vaz, M.A., Mora, J., Garcia del Muro, X., Gutierrez, A., Tous, C., Carnero, A., Marcilla, D., Carranza, A., Sancho, P., Martinez-Trufero, J., Diaz-Beveridge, R., Cruz, J., Encinas, V., Taron, M., Moura, D.S., Luna, P., Hindi, N., Lopez-Pousa, A.

“…Patients with relapsed unresectable osteosarcoma represents an unmet need, so active and safe systemic treatments are required. Fas cell surface death receptor…”
Get full text

Phase I II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study by LOPEZ-POUSA, A, LOSA, R, MARTINEZ-TRUFERO, J, ESTEBAN, E, BUESA, J. M, MARTIN, J, MAUREL, J, FRA, J, SIERRA, M, CASADO, A, GARCIA DEL MURO, J, POVEDA, A, BALANA, C

“…The aim of the study was to determine the dose-limiting toxicity and maximum tolerated dose of a first-line combination of doxorubicin and gemcitabine in adult…”
Get full text

Association of immune-related adverse (irAEs) with immune-checkpoint inhibitors (ICIs) efficacy in solid tumors by Riudavets Melia, M., del Carpio, L.P., Gabriela Sullivan, I., Barba Joaquín, A., Maroto Rey, P., Anguera Palacios, G., Páez López-Bravo, D., Callejo Pérez, A., González Blanco, C., Castillo Villegas, D., Facundo Molas, C., Garcia Planella, E., Genua Trullos, I., López Pousa, A., Sebio García, A., Martín Lorente, C., Virgili Manrique, A.C., Gallego Rubio, O., Barnadas Molins, A., Majem Tarruella, M.

Get full text

Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 1) by Mañós, M, Giralt, J, Rueda, A, Cabrera, J, Martinez-Trufero, J, Marruecos, J, Lopez-Pousa, A, Rodrigo, J.P, Castelo, B, Martínez-Galán, J, Arias, F, Chaves, M, Herranz, J.J, Arrazubi, V, Baste, N, Castro, A, Mesía, R

“…Highlights • Spanish Multidisciplinary consensus on squamus cell neoplasm os the head and neck. • Multidisciplinary approach for larynx/hypopharynx tumors. •…”
Get full text

Phase II clinical trial with pegylated liposomal doxorubicin (CAELYX®/Doxil®) and quality of life evaluation (EORTC QLQ-C30) in adult patients with advanced soft tissue sarcomas A study of the Spanish Group for Research in Sarcomas (GEIS) by Poveda, A., López-Pousa, A., Martín, J., Del Muro, J. García, Bernabé, R., Casado, A., Balañá, C., Sanmartín, O., Menéndez, M. D., Escudero, P., Cruz, J., Belyakova, Elena, Menéndez, D., Buesa, J. M.

“…Background: Pegylated liposomal doxorubicin (PLD), a formulation with pharmacokinetic differences with respect to doxorubicin (DXR), might benefit patients…”
Get full text

Phase II Trial of Doxorubicin Plus Escalated High-Dose Ifosfamide in Patients With Advanced Soft Tissue Sarcomas of the Adult: A Study of the Spanish Group for Research on Sarcomas (GEIS) by Buesa, J.M, Garcia del Muro, J, Cruz, J, Montalar, J, Escudero, P, Martin, J, Maurel, J, Lopez-Pousa, A, de las Penas, R, Casado, A

“…Background. To explore the tolerance and the activity of high-dose ifosfamide (IFOS) combined with doxorubicin (DXR) at 50 mg/m(2) every 4 weeks in patients…”
Get full text

Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: Results from an integrated analysis by von Minckwitz, G, Schwenkglenks, M, Skacel, T, Lyman, G.H, Pousa, A. Lopez, Bacon, P, Easton, V, Aapro, M.S

“…Abstract Granulocyte colony-stimulating factors (G-CSFs) reduce febrile neutropaenia (FN) incidence but may be used inconsistently in current practice (CP)…”
Get full text

Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: A study of the Spanish Group for Research on Sarcomas (GEIS) by Buesa, J. M., López-Pousa, A., Martín, J., Antón, A., García del Muro, J., Bellmunt, J., Arranz, F., Valentí, V., Escudero, P., Menéndez, D., Casado, A., Poveda, A.

“…Background: The agent Ifosfamide (IFOS) is active against soft tissue sarcomas (STS), and patients who progress to IFOS at doses ≤ 10 g/m2 show remissions when…”
Get full text